The funding will be funnelled into an unnamed p53 suppressor-focused oncology Weizmann spinout and ultrasound guidance device maker On-Sight Medical.

Two Israel-based health spinouts of Weizmann Institute of Science have collectively secured $12m in funding from biomedicine developer BioLeaders and VC firm Yozma Group Asia. The capital includes $10m supplied by BioLeaders, itself backed by Yozma, for a new, as-yet unnamed Weizmann Institute-founded oncology spinout. The investment is anticipated to close in the coming months.…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.